📢 The wait is over: Abstracts for the 68th ASH Annual Meeting and Exposition are live!
More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26.
Browse now: https://ow.ly/rm4O5103Lx8
#HemeSky #OncSky
More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26.
Browse now: https://ow.ly/rm4O5103Lx8
#HemeSky #OncSky
November 4, 2026 at 3:45 PM
📢 The wait is over: Abstracts for the 68th ASH Annual Meeting and Exposition are live!
More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26.
Browse now: https://ow.ly/rm4O5103Lx8
#HemeSky #OncSky
More than 6,300 abstracts have been accepted for oral and poster presentations at #ASH26.
Browse now: https://ow.ly/rm4O5103Lx8
#HemeSky #OncSky
International attendees are valued members of the ASH community and are always welcome at the ASH annual meeting.
Check out resources to help you navigate the visa application process and explore flexible #ASH26 registration options: https://ow.ly/p9u451038gh
#HemeSky #MedSky #Hematology
Check out resources to help you navigate the visa application process and explore flexible #ASH26 registration options: https://ow.ly/p9u451038gh
#HemeSky #MedSky #Hematology
November 3, 2026 at 10:00 PM
International attendees are valued members of the ASH community and are always welcome at the ASH annual meeting.
Check out resources to help you navigate the visa application process and explore flexible #ASH26 registration options: https://ow.ly/p9u451038gh
#HemeSky #MedSky #Hematology
Check out resources to help you navigate the visa application process and explore flexible #ASH26 registration options: https://ow.ly/p9u451038gh
#HemeSky #MedSky #Hematology
You’re already mentoring medical students. Make it official with a title and support! Get training, funding, and a network to help you establish a #hematology Student Interest Group at your DO or MD medical school.
Apply now: https://ow.ly/jcoC5103ISM #HemeSky #MedSky
Apply now: https://ow.ly/jcoC5103ISM #HemeSky #MedSky
November 4, 2026 at 7:25 PM
You’re already mentoring medical students. Make it official with a title and support! Get training, funding, and a network to help you establish a #hematology Student Interest Group at your DO or MD medical school.
Apply now: https://ow.ly/jcoC5103ISM #HemeSky #MedSky
Apply now: https://ow.ly/jcoC5103ISM #HemeSky #MedSky
October 28, 2026 at 6:36 PM
We're pleased to share news of the publication of Simon Fletcher's lived experience model for #psychosocial support in the age of #haemophilia #genetherapy as a Letter to the Editor in Haemophilia.
#HemeSky #MedSky
#HemeSky #MedSky
November 3, 2026 at 8:30 AM
We're pleased to share news of the publication of Simon Fletcher's lived experience model for #psychosocial support in the age of #haemophilia #genetherapy as a Letter to the Editor in Haemophilia.
#HemeSky #MedSky
#HemeSky #MedSky
CAR-T cell therapy has transformed blood cancer treatment, but solid tumors remain a major challenge. A new review explores how cell engineering, immune cell therapies, & combination strategies could improve cancer treatment.
doi.org/10.46765/267...
#HemeOnc #HemeSky #JBMTCT @ctc-usp.bsky.social
doi.org/10.46765/267...
#HemeOnc #HemeSky #JBMTCT @ctc-usp.bsky.social
November 4, 2026 at 1:22 PM
CAR-T cell therapy has transformed blood cancer treatment, but solid tumors remain a major challenge. A new review explores how cell engineering, immune cell therapies, & combination strategies could improve cancer treatment.
doi.org/10.46765/267...
#HemeOnc #HemeSky #JBMTCT @ctc-usp.bsky.social
doi.org/10.46765/267...
#HemeOnc #HemeSky #JBMTCT @ctc-usp.bsky.social
Promising new studies highlight the potential of GLP-1 receptor agonists as credible, effective treatment options for individuals with #sicklecell disease.
Read more in The Hematologist: https://ow.ly/ZOy35102qFF
#Hematology #HemeSky #Medsky (Dr Sonia Wolf) — Bluesky
Read more in The Hematologist: https://ow.ly/ZOy35102qFF
#Hematology #HemeSky #Medsky (Dr Sonia Wolf) — Bluesky
October 30, 2026 at 1:15 PM
Promising new studies highlight the potential of GLP-1 receptor agonists as credible, effective treatment options for individuals with #sicklecell disease.
Read more in The Hematologist: https://ow.ly/ZOy35102qFF
#Hematology #HemeSky #Medsky (Dr Sonia Wolf) — Bluesky
Read more in The Hematologist: https://ow.ly/ZOy35102qFF
#Hematology #HemeSky #Medsky (Dr Sonia Wolf) — Bluesky
Not a fan of how these turned out. Supposedly monocytic cells? Lower right one resembles a goblet cell to me
#art - #digitalart - #hemesky
#art - #digitalart - #hemesky
October 26, 2026 at 8:08 PM
Not a fan of how these turned out. Supposedly monocytic cells? Lower right one resembles a goblet cell to me
#art - #digitalart - #hemesky
#art - #digitalart - #hemesky
Take the science of the 68th ASH Annual Meeting and Exposition beyond #ASH26.
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/piJT51016gZ
#HemeSky #OncSky
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/piJT51016gZ
#HemeSky #OncSky
October 27, 2026 at 6:00 PM
Take the science of the 68th ASH Annual Meeting and Exposition beyond #ASH26.
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/piJT51016gZ
#HemeSky #OncSky
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/piJT51016gZ
#HemeSky #OncSky
Learning to Live compared experiences of people who have always lived with moderate or mild #haemophilia with those who were severe but effectively now have a moderate or mild phenotype due to #treatment. Results are now available to read in #BDCP
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
October 28, 2026 at 9:57 AM
Learning to Live compared experiences of people who have always lived with moderate or mild #haemophilia with those who were severe but effectively now have a moderate or mild phenotype due to #treatment. Results are now available to read in #BDCP
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
Learning to Live compared experiences of people who have always lived with moderate or mild #haemophilia with those who were severe but effectively now have a moderate or mild phenotype due to #treatment. Results are now available to read in #BDCP
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
October 28, 2026 at 9:57 AM
Learning to Live compared experiences of people who have always lived with moderate or mild #haemophilia with those who were severe but effectively now have a moderate or mild phenotype due to #treatment. Results are now available to read in #BDCP
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
🔗 loom.ly/87m1P_8
#HemeSky #MedSky
⏰ Last call for #ASH26 late-breaking abstracts!
Have timely, high-impact research findings to share? Submit your abstract for consideration by October 28, 2026. https://ow.ly/WxXP50ZXHXH
#HemeSky #MedSky #OncSky
Have timely, high-impact research findings to share? Submit your abstract for consideration by October 28, 2026. https://ow.ly/WxXP50ZXHXH
#HemeSky #MedSky #OncSky
October 27, 2026 at 2:00 PM
⏰ Last call for #ASH26 late-breaking abstracts!
Have timely, high-impact research findings to share? Submit your abstract for consideration by October 28, 2026. https://ow.ly/WxXP50ZXHXH
#HemeSky #MedSky #OncSky
Have timely, high-impact research findings to share? Submit your abstract for consideration by October 28, 2026. https://ow.ly/WxXP50ZXHXH
#HemeSky #MedSky #OncSky
Learning to Live compared experiences of people who have always lived with moderate or mild #haemophilia with those who were severe but effectively now have a moderate or mild phenotype due to #treatment. Results are now available to read in #BDCP
🔗 https://loom.ly/87m1P_8
#HemeSky #MedSky
🔗 https://loom.ly/87m1P_8
#HemeSky #MedSky
October 28, 2026 at 8:30 AM
Learning to Live compared experiences of people who have always lived with moderate or mild #haemophilia with those who were severe but effectively now have a moderate or mild phenotype due to #treatment. Results are now available to read in #BDCP
🔗 https://loom.ly/87m1P_8
#HemeSky #MedSky
🔗 https://loom.ly/87m1P_8
#HemeSky #MedSky
Take the science of the 68th ASH Annual Meeting and Exposition beyond #ASH26.
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/LIBm5101xFk
#HemeSky #OncSky
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/LIBm5101xFk
#HemeSky #OncSky
October 27, 2026 at 10:02 PM
Take the science of the 68th ASH Annual Meeting and Exposition beyond #ASH26.
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/LIBm5101xFk
#HemeSky #OncSky
Explore key research with leading experts at the 2027 Highlights of ASH and connect with colleagues around the world.
Register now: https://ow.ly/LIBm5101xFk
#HemeSky #OncSky
ASH's new 2026 Iron Deficiency Strategic Blueprint outlines a roadmap to improve awareness, diagnosis, care delivery, and research to reduce the burden of #irondeficiency and iron-deficiency anemia.
Explore the blueprint: https://ow.ly/pFQG5100wjL
#HemeSky
Explore the blueprint: https://ow.ly/pFQG5100wjL
#HemeSky
October 23, 2026 at 4:01 PM
ASH's new 2026 Iron Deficiency Strategic Blueprint outlines a roadmap to improve awareness, diagnosis, care delivery, and research to reduce the burden of #irondeficiency and iron-deficiency anemia.
Explore the blueprint: https://ow.ly/pFQG5100wjL
#HemeSky
Explore the blueprint: https://ow.ly/pFQG5100wjL
#HemeSky
🚨 ASH members: Your voice is needed NOW.
Congress must pass the Sickle Cell Disease Comprehensive Care Act (H.R. 5178 / S. 721) before the end of the year. Contact your lawmakers and urge them to act for people living with #SCD.
https://ow.ly/FXiM51005fg
#ConquerSCD #HemeSky
Congress must pass the Sickle Cell Disease Comprehensive Care Act (H.R. 5178 / S. 721) before the end of the year. Contact your lawmakers and urge them to act for people living with #SCD.
https://ow.ly/FXiM51005fg
#ConquerSCD #HemeSky
October 24, 2026 at 3:00 PM
🚨 ASH members: Your voice is needed NOW.
Congress must pass the Sickle Cell Disease Comprehensive Care Act (H.R. 5178 / S. 721) before the end of the year. Contact your lawmakers and urge them to act for people living with #SCD.
https://ow.ly/FXiM51005fg
#ConquerSCD #HemeSky
Congress must pass the Sickle Cell Disease Comprehensive Care Act (H.R. 5178 / S. 721) before the end of the year. Contact your lawmakers and urge them to act for people living with #SCD.
https://ow.ly/FXiM51005fg
#ConquerSCD #HemeSky
ASH is at #OMED2026! 👋 Attending the conference? Stop by booth 424 to connect with ASH and learn more about the Society's resources and opportunities for the hematology community. See you there!
#Hematology #HemeSky
#Hematology #HemeSky
October 23, 2026 at 5:15 PM
ASH is at #OMED2026! 👋 Attending the conference? Stop by booth 424 to connect with ASH and learn more about the Society's resources and opportunities for the hematology community. See you there!
#Hematology #HemeSky
#Hematology #HemeSky
Allogeneic hematopoietic stem cell transplantation remains the standard curative treatment for eligible adults w/ sickle cell disease. Alternative donor sources are expanding therapeutic options, while evidence for adults with thalassemia remains limited.
doi.org/10.46765/267...
#HemeSky #hematology
doi.org/10.46765/267...
#HemeSky #hematology
October 23, 2026 at 1:51 PM
Allogeneic hematopoietic stem cell transplantation remains the standard curative treatment for eligible adults w/ sickle cell disease. Alternative donor sources are expanding therapeutic options, while evidence for adults with thalassemia remains limited.
doi.org/10.46765/267...
#HemeSky #hematology
doi.org/10.46765/267...
#HemeSky #hematology
🩸 Come visit ASH at #OMED2026! Learn, connect, and explore the world of #hematology: https://ow.ly/3FKf50ZYrbx
#MedSky #HemeOnc #HemeSky
#MedSky #HemeOnc #HemeSky
October 22, 2026 at 2:00 PM
🩸 Come visit ASH at #OMED2026! Learn, connect, and explore the world of #hematology: https://ow.ly/3FKf50ZYrbx
#MedSky #HemeOnc #HemeSky
#MedSky #HemeOnc #HemeSky
⏰ Time is running out: Congress must act before the end of the year to pass the Sickle Cell Disease Comprehensive Care Act.
ASH Members: ASH needs your voice NOW. Tell your lawmakers to help move this critical legislation forward this year. https://ow.ly/bZKE510055p
#ConquerSCD #HemeSky
ASH Members: ASH needs your voice NOW. Tell your lawmakers to help move this critical legislation forward this year. https://ow.ly/bZKE510055p
#ConquerSCD #HemeSky
October 22, 2026 at 3:00 PM
⏰ Time is running out: Congress must act before the end of the year to pass the Sickle Cell Disease Comprehensive Care Act.
ASH Members: ASH needs your voice NOW. Tell your lawmakers to help move this critical legislation forward this year. https://ow.ly/bZKE510055p
#ConquerSCD #HemeSky
ASH Members: ASH needs your voice NOW. Tell your lawmakers to help move this critical legislation forward this year. https://ow.ly/bZKE510055p
#ConquerSCD #HemeSky
🍁 New & forthcoming in #BDCP this month:
🇺🇸 Case series on perioperative use of bypassing agent #eptacogbeta in #haemophilia A & major #surgery
🇬🇧 Qualitative study exploring #treatment disparities and #QoL impacts in non-severe haemophilia
🔗 https://loom.ly/uIXcNF8
#HemeSky #MedSky
🇺🇸 Case series on perioperative use of bypassing agent #eptacogbeta in #haemophilia A & major #surgery
🇬🇧 Qualitative study exploring #treatment disparities and #QoL impacts in non-severe haemophilia
🔗 https://loom.ly/uIXcNF8
#HemeSky #MedSky
October 22, 2026 at 7:01 AM
🍁 New & forthcoming in #BDCP this month:
🇺🇸 Case series on perioperative use of bypassing agent #eptacogbeta in #haemophilia A & major #surgery
🇬🇧 Qualitative study exploring #treatment disparities and #QoL impacts in non-severe haemophilia
🔗 https://loom.ly/uIXcNF8
#HemeSky #MedSky
🇺🇸 Case series on perioperative use of bypassing agent #eptacogbeta in #haemophilia A & major #surgery
🇬🇧 Qualitative study exploring #treatment disparities and #QoL impacts in non-severe haemophilia
🔗 https://loom.ly/uIXcNF8
#HemeSky #MedSky
Tomorrow is the day! Will you be there?
Explore how natural language processing might help extract valuable outcomes from electronic medical records. Register now: https://ow.ly/7VpG50ZZ42G
#Hematology #HemeSky #MedSky
Explore how natural language processing might help extract valuable outcomes from electronic medical records. Register now: https://ow.ly/7VpG50ZZ42G
#Hematology #HemeSky #MedSky
October 21, 2026 at 12:00 PM
Tomorrow is the day! Will you be there?
Explore how natural language processing might help extract valuable outcomes from electronic medical records. Register now: https://ow.ly/7VpG50ZZ42G
#Hematology #HemeSky #MedSky
Explore how natural language processing might help extract valuable outcomes from electronic medical records. Register now: https://ow.ly/7VpG50ZZ42G
#Hematology #HemeSky #MedSky
If you research hematologic diseases that disproportionately affect underserved communities, you may be eligible for research funding through the ASH Treating Fairly Research Award.
Apply by Nov. 15. Learn more: https://ow.ly/lMsN50ZZ4VE #Fight4Hematology #ASHAwards #HemeSky #MedSky
Apply by Nov. 15. Learn more: https://ow.ly/lMsN50ZZ4VE #Fight4Hematology #ASHAwards #HemeSky #MedSky
October 21, 2026 at 6:00 PM
If you research hematologic diseases that disproportionately affect underserved communities, you may be eligible for research funding through the ASH Treating Fairly Research Award.
Apply by Nov. 15. Learn more: https://ow.ly/lMsN50ZZ4VE #Fight4Hematology #ASHAwards #HemeSky #MedSky
Apply by Nov. 15. Learn more: https://ow.ly/lMsN50ZZ4VE #Fight4Hematology #ASHAwards #HemeSky #MedSky
Updated Brazilian consensus guidelines address the prevention and treatment of acute and GVHD after allogeneic HCT, incorporating evidence on prophylactic strategies and emerging therapies, including ruxolitinib and axatilimab.
🆓 doi.org/10.46765/267... #MedSky #HemeOnc #HemeSky
🆓 doi.org/10.46765/267... #MedSky #HemeOnc #HemeSky
October 21, 2026 at 1:20 PM
Updated Brazilian consensus guidelines address the prevention and treatment of acute and GVHD after allogeneic HCT, incorporating evidence on prophylactic strategies and emerging therapies, including ruxolitinib and axatilimab.
🆓 doi.org/10.46765/267... #MedSky #HemeOnc #HemeSky
🆓 doi.org/10.46765/267... #MedSky #HemeOnc #HemeSky
Last chance to save on #ASH26 registration!
Secure advance registration rates for the 68th ASH Annual Meeting and Exposition before prices increase on October 22.
Register now: https://ow.ly/WGwO50ZZ3Zr
#HemeSky #OncSky #MedSky
Secure advance registration rates for the 68th ASH Annual Meeting and Exposition before prices increase on October 22.
Register now: https://ow.ly/WGwO50ZZ3Zr
#HemeSky #OncSky #MedSky
October 20, 2026 at 2:01 PM
Last chance to save on #ASH26 registration!
Secure advance registration rates for the 68th ASH Annual Meeting and Exposition before prices increase on October 22.
Register now: https://ow.ly/WGwO50ZZ3Zr
#HemeSky #OncSky #MedSky
Secure advance registration rates for the 68th ASH Annual Meeting and Exposition before prices increase on October 22.
Register now: https://ow.ly/WGwO50ZZ3Zr
#HemeSky #OncSky #MedSky